News
Dupixent Prefilled Pen Approval Provides Additional Administration Option
The FDA has approved a prefilled pen formulation of Dupixent (dupilumab; Sanofi and Regeneron), providing another option for administering the treatment.
Your search for oral corticosteroids returned 171 results
News
Guideline Details Pharmacologic Management of COPD
Clinical practice guideline addresses 6 emerging questions around COPD management.
Drugs in the Pipeline
Voclosporin NDA for Lupus Nephritis Submitted to FDA
The New Drug Application (NDA) for voclosporin (Aurinia Pharmaceuticals) has been submitted to the Food and Drug Administration (FDA) for the treatment for lupus nephritis.
News
Dupixent Approval Expanded to Pediatric Patients With Atopic Dermatitis
The FDA has expanded the approval of Dupixent® (dupilumab; Regeneron and Sanofi) to include patients aged 6 to 11 years with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Clinical Charts
Chemotherapy-Induced Nausea and Vomiting Guidelines: Prophylaxis
The ASCO guideline provides updated recommendations for the prevention and management of chemotherapy-induced nausea and vomiting (CINV) based on the emetic risk of the treatment regimen.
ATS 2020
Masitinib Significantly Reduced Exacerbations in Uncontrolled Severe Asthma
The first-in-class tyrosine kinase inhibitor masitinib decreased asthma exacerbations greater than placebo in patients with severe asthma uncontrolled by oral corticosteroids.
ATS 2020
COPD Maintenance Therapy: Adverse Outcomes With Tiotropium/Olodaterol vs LABA/ICS
In patients with COPD, tiotropium/olodaterol was associated with a lower risk for escalation to triple therapy or the development of adverse outcomes compared with LABA/ICS.
Drugs in the Pipeline
Pipeline: Immunotherapies and Other Investigational Therapies for COVID-19
Updated on 6/16 While no specific treatment for coronavirus disease 2019 (COVID-19) is currently available, several therapies are being investigated globally.* AB201 (ARCA biopharma): a selective inhibitor of tissue factor being developed as a potential treatment for COVID associated coagulopathy. Clinical testing is expected to begin in the second half of 2020. Acalabrutinib (AstraZeneca): a…
News
NIH Treatment Guidelines for COVID-19 Released
Recommendations on the management of coronavirus disease 2019 (COVID-19) were recently released by the National Institutes of Health (NIH) to help guide clinicians caring for patients with COVID-19.
News
ACAAI: Statement on Corticosteroid Use for Allergies, Asthma During COVID-19 Pandemic
The American College of Allergy, Asthma and Immunology (ACAAI) has issued a statement regarding the use of corticosteroids for patients with allergies and asthma.
